Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
P/E ratio for Day One Biopharmaceuticals, Inc. (DAWN)
P/E ratio as of 2023: -6.17
According to Day One Biopharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.17. At the end of 2022 the company had a P/E ratio of -10.66.
P/E ratio history for Day One Biopharmaceuticals, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.17 |
| 2022 | -10.66 |
| 2021 | -14.82 |
| 2020 | -35.93 |
| 2019 | -98.93 |